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Abstract There is evidence that the β-common receptor (βcR) plays a pivotal role in the 
tissue-protective (non-hematopoietic) effects of erythropoietin (EPO). This study was 
designed to investigate whether EPO reduces the acute kidney injury (AKI) caused by sepsis 
in the mouse and whether this effect is mediated by the βcR. In two months old C57BL/6 wild 
type and βcR knockout mice, lipopolysaccharide (9 mg/kg for 18 h) caused a significant 
increase in urea and creatinine and, hence, AKI. This AKI was not associated with any overt 
morphological alterations in the kidney. The AKI was attenuated by EPO (1000 IU/kg, 1 h after 
lipopolysaccharide) in wild type mice, but not in βcR knockout mice. In kidneys of endotoxemic 
wild type mice, EPO enhanced the phosphorylation of Akt, glycogen synthase kinase-3β and 
endothelial nitric oxide synthase and inhibited the activation of nuclear factor-ĸB. All of these 
effects of EPO were lost in βcR knockout mice. Sepsis is more severe in older animals or 
patients.  Eight months old wild type and βcR knockout mice that underwent cecal ligation and 
puncture developed AKI at 24 h, which was attenuated by EPO (1000 IU/kg, 1 h post cecal 
ligation and puncture) in wild type mice, but not in βcR knockout mice. In conclusion, we report, 
for the first time, that the activation of the βcR by EPO is essential for the observed reduction 
in AKI in either endotoxemia (young mice) or polymicrobial sepsis (old mice), and for the 
activation of well-known signaling pathways by EPO.  
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Introduction 
Sepsis is a complex clinical entity caused by an individual’s systemic response to an infection 
with a wide range of clinical symptoms often leading to multiple organ dysfunction syndrome 
(MODS) and ultimately multiple organ failure (MOF). Despite a substantially improved 
knowledge of the pathophysiology of sepsis, the treatment of this condition is still a clinical 
challenge. To date, therapies have been mostly supportive and all specific therapeutic 
approaches, except early administration of antibiotics and “early goal directed therapy” 1, 2, 
have failed to be translated successfully into the clinical setting. Hence, new pharmacological 
strategies are urgently needed to improve this condition. In sepsis some organs can escape 
relatively unscathed, whereas others become affected both early and severely 3. The kidney 
is one such organ that can be affected early with the development of acute kidney injury (AKI). 
This dysfunction is one of the most frequent and serious complications of sepsis and septic 
shock 4. According to the Acute Kidney Injury Network consensus conference in 2007, AKI is 
diagnosed as an abrupt (within 48 hours) reduction in kidney function defined as an absolute 
increase in serum creatinine (≥ 26.4 μmol/l), a percentage increase in serum creatinine (≥ 1.5-
fold from baseline), or a reduction in urine output (≤ 0.5 ml/kg per h for more than 6 h) 5. It is 
interesting to note that this definition does not take into consideration histological evidence of 
tissue injury and is solely based on rise in creatinine or fall in urinary output - even though the 
word injury may imply the existence of morphological evidence of injury 6. 
Interestingly, the incidence of AKI increases with the severity of sepsis, occurring in 19 % of 
patients with sepsis, 23 % patients with severe sepsis and 51 % patients with septic shock 7. 
Sepsis occurs more frequently and severely in older patients 8 and there is some evidence 
that the elderly septic patient is more susceptible for the development of AKI 9. Similarly, in 
animal models of experimental sepsis systemic inflammation and the release of pro-
inflammatory cytokines are greater in older animals 10-12 and the severity of septic AKI was 
recently reported to be age-dependent in female mice 13. It has been proposed that the 
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increase in the severity of sepsis in aging animals is secondary to changes in gut flora (Hyde 
et al., 1990). 
Emerging evidence suggests that the pathogenesis of septic renal dysfunction involves 
distinct mechanisms when compared to a non-septic etiology 14. There is evidence in man, 
that the AKI caused by sepsis is not associated (or at least solely explained) by significant 
morphological changes such as extensive tubular necrosis 6, 15. The proposed 
pathophysiological mechanisms of sepsis-associated AKI include systemic vasodilatation, 
intra-renal vasoconstriction, inflammation and bioenergetics failure 14, 16 6, 7, 17. 
The pleiotropic hormone erythropoietin (EPO) is known to possess organ protective 
properties, which are independent from its well-established hematopoietic effects 18. 
Endogenous EPO is primarily produced by renal cortical fibroblasts, and the fact, that 
erythropoietin receptors (EPO-R) are expressed in glomerular, endothelial and tubular 
epithelial cells 19, 20, suggests endogenous EPO may function in a paracrine manner to limit 
the extent of injury after a noxious stimulus 19. Furthermore, studies have proposed that the 
tissue protective effects of EPO are mediated through a ‘tissue-protective’ receptor, which is 
pharmacologically distinct from the classical hematopoietic EPO-R 21. This tissue protective 
receptor is a heterocomplex composed of EPO-R and the β-common receptor (βcR), which 
exhibits a lower affinity for EPO 22. Over the years, EPO has been shown to be protective in 
various animal models of injury including cerebral ischemia 23, 24, myocardial ischemia 25-27, 
and renal injury 28-30. Indeed, in a model of bilateral renal artery occlusion in the rat, EPO 
inhibits apoptotic cell death, promotes renal functional recovery, and enhances tubular 
epithelial regeneration 19.  
It should be noted that the effects of EPO in sepsis-induced AKI are controversial 31-36. Some 
studies report no beneficial effect of EPO in models of endotoxemia in the rat or pig 31; 32. In 
contrast, other studies have shown that EPO exerts beneficial effects in experimental sepsis. 
In 2007, Mitra et al. reported for the first time that pretreatment with EPO reduces the renal 
dysfunction in the mouse 34. Moreover, administration of EPO given 1 h after endotoxin or CLP 
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reduces renal dysfunction and mortality in mice 35. Pessoa de Souza et al. recently reported 
their extensive investigation that pre- or post-treatment with high-dose EPO (4000 IU/kg) 
exhibited anti-inflammatory effects, improved survival as well as renal function in a rat model 
of sepsis. However, none of the above (positive) studies investigated the role of the βcR in 
either the observed effects or the signaling events initiated by EPO. 
This study investigates the effects of EPO and specifically, the role of the βcR in the renal 
dysfunction caused by endotoxemia [lipopolysaccharide (LPS)] or polymicrobial sepsis [cecal 
ligation and puncture (CLP)].  
Results 
Effect of EPO on renal dysfunction in endotoxemic WT and βcR KO mice 
When compared to sham mice treated with saline, WT mice subjected to 18 h of endotoxemia 
demonstrated a significant increase in both serum urea (7.3 ±. 0.27 vs. 33.1 ±.1.75 mmol/l, 
P<0.05, Figure 1A) and serum creatinine (25.9 ± 0.92 vs. 57.1 ± 4.72 μmol/l, P<0.05, Figure 
1C), indicating the development of AKI. Administration of EPO significantly attenuated the rise 
in serum urea (33.1 ± 1.75 vs. 25.9 ± 3.2 mmol/l, P<0.05, Figure 1A) and creatinine (57.1 ± 
4.72 vs. 38.2 ± 2.47 μmol/l, P<0.05, Figure 1C). To investigate the role of the proposed tissue 
protective receptor in LPS-induced AKI for the beneficial properties of EPO reported above, 
we have evaluated the effect of EPO on serum urea and creatinine in βcR KO mice. When 
compared to sham βcR KO mice treated with saline, βcR KO mice subjected to 18 h of 
endotoxemia demonstrated a significant increase in serum urea (8.3 ± 0.55 vs. 33.0 ± 1.94 
mmol/l, P<0.05, Figure 1B) and creatinine (27.8 ± 0.81 vs. 59.4 ± 5.06 μmol/l, P<0.05; Figure 
1D). Most notably, the renal dysfunction caused by endotoxemia in βcR KO mice was not 
attenuated by EPO (urea 33.0 ± 1.94 vs. 34 ± 1.27 mmol/l, P>0.05, Figure 1B; creatinine 59.4 
± 5.06 vs. 54.9  ± 3.06 μmol/l, P>0.05, Figure 1D). 
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Effects of endotoxemia and/or EPO on renal morphology (light microscopy) and 
immunohistochemical staining for apoptosis [cleaved caspase-3 (CCR3)] kidney injury 
molecule-1 (KIM-1) 
To gain a better understanding of the mechanisms underlying the observed renal dysfunction 
in endotoxemia, we carried out an extensive histological analysis in all experimental groups. 
Evaluation by light microscopy (HE-staining) revealed that there was no overt morphological 
evidence of proximal tubular epithelial cell injury, interstitial edema, interstitial inflammation, 
vasculopathy or glomerular abnormality in any of the study groups (Figure 2A). Therefore the 
results of the HE pathology evaluation produced no significant treatment-related changes.  
To further investigate the potential role of apoptosis in the observed renal dysfunction, we 
analyzed all sections for the active fragment of caspase-3 (CCR3), which plays a key role in 
apoptosis. Immunohistochemical analysis for CCR3 revealed that CCR3 staining was 
characterized by generally minimal or very minimal staining of individual or small clumps of 
cells predominantly within the medulla but scattered positively stained cells were also visible 
throughout the kidney within glomeruli/tubulointerstitial spaces and blood vessels. Overall, we 
found no staining in sham-operated animals and a small increase in staining in all animals 
subjected to endotoxemia with no significant treatment-related changes. (Figure 2B, P>0.05).  
To further investigate the potential role of proximal tubular injury in the observed renal 
dysfunction, we analyzed all sections for KIM-1, an early biomarker of proximal tubular injury. 
KIM-1 staining was characterized by generally diffuse staining of the whole kidney with positive 
staining presenting as areas of multi-focal to diffuse increased staining intensity within the pars 
recta region of the kidney.  Compared with sham operated WT animals. The results of the 
Kim-1 IHC pathology evaluation showed slightly increased staining in the endotoxemic WT 
mice, which appeared reduced after treatment with EPO. However, the magnitude of the 
changes was small. This evaluation was, therefore, repeated by blind re-reading of groups by 
the original study pathologist and by a second pathologist (data not shown) and confirmed that 
there was indeed a small difference. There was no treatment-related change in the βcR KO 
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mice. Overall, none of the observed changes in KIM-1 immunohistochemistry were statistically 
significant (P>0.05, Figure 2 C). 
Effect of EPO on the phosphorylation of Akt, glycogen synthase kinase-3β (GSK)-3β 
and endothelial nitric oxide synthase (eNOS) and on the nuclear translocation of the 
p65 nuclear factor (NF)-ĸB subunit in the kidneys of endotoxemic WT and βcR KO mice 
To gain a better insight into the potential mechanism(s) underlying the observed beneficial 
effects of EPO, we investigated the effects of this hormone on cell signaling pathways in the 
kidneys of WT and βcR KO mice, known to confer tissue protection or to inhibit inflammation. 
When compared to kidneys of sham mice treated with saline, kidneys of WT and βcR KO mice 
subjected to LPS demonstrated no change in the total Akt content and the phosphorylation of 
Akt on Ser473 (Figure 3A), total GSK-3β content and the phosphorylation of GSK-3β on Ser9 
(Figure 3B) or total eNOS content and phosphorylation of eNOS on Ser1177 (Figure 3C). 
Treatment of endotoxemic WT mice with EPO, however, resulted in a substantial increase in 
the phosphorylation of serine residues on Akt (Figure 3A), GSK-3β (Figure 3B), and eNOS 
(Figure 3C). In contrast, administration of EPO to endotoxemic βcR KO mice caused no 
change in the phosphorylation of Akt (Figure 3A), GSK-3β (Figure 3B), and eNOS (Figure 3C).  
When compared to kidneys from sham mice treated with saline, the kidneys of endotoxemic 
WT and βcR KO mice exhibited significant increases in the nuclear translocation of the p65 
NF-ĸB subunit (Figure 3D), indicating the activation of NF-ĸB. Treatment of endotoxemic WT 
mice with EPO resulted in a significant reduction in nuclear translocation of p65 and, hence, 
inhibition of activation of NF-ĸB in the kidney (Figure 3D). In contrast, administration of EPO 
to endotoxemic βcR KO mice did not attenuate the nuclear translocation of p65 caused by 
LPS (Figure 3D). 
The development of renal dysfunction in aging mice following cecal ligation and 
puncture (CLP).  
The development of renal dysfunction in our short and severe model of polymicrobial sepsis 
via CLP is strongly age-dependent. Compared to sham-operated animals (26.3 ± 0.72 μmol/l), 
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we could not determine a significant renal dysfunction (determined by changes in serum 
creatinine) 24 h after CLP in two (25.7 ± 1.13 μmol/l) and five months (38.1 ± 6.2 μmol/l) old 
WT mice, which underwent CLP surgery. However, when compared to sham-operated mice, 
eight months old WT mice, that underwent CLP surgery, developed a significant and reliable 
increase in serum creatinine (26.3 ± 0.72 vs. 84.6 ± 7.34 μmol/l, P<0.05, Figure 4). 
Effect of EPO on renal dysfunction in WT and βcR KO mice that underwent CLP 
When compared to sham-operated WT mice, eight months old WT and βcR KO mice that 
underwent CLP surgery demonstrated a significant increase in serum creatinine (WT mice 
26.3 ± 0.72 vs. 76.3 ± 8.01 μmol/l, P<0.05, Figure 5A; KO mice 23.2 ± 6.44 vs. 82.1 ± 11.77 
μmol/l, P<0.05, Figure 5B). Administration of EPO to septic WT mice significantly attenuated 
the rise in serum creatinine (76.3 ± 8.01 vs. 49.9 vs. 6.54 μmol/l, P<0.05, Figure 5A). Most 
notably, the renal dysfunction caused by CLP in βcR KO mice was not attenuated by EPO 
(82.1 ± 11.77 μmol/l, 71.4 ± 10.81, P>0.05, Figure 5B). 
Expression of CSf2rb (encoding the βcR) mRNA in medulla and cortex of the kidneys 
of WT sham mice. 
To gain a better insight into where the βcR was expressed in the mouse kidneys, we attempted 
to detect the CSf2rb gene (which encodes the βcR, which was modified in the βcR knockout 
mice used in this study). We, therefore, isolated mRNA from medulla and cortex of the kidneys 
of WT sham mice and subjected the cDNA obtained after reverse transcription of mRNA to a 
PCR protocol with appropriate primers (see Tab. S1 online supplementary). We could clearly 
detect presence of βcR mRNA in both cortex and medulla (Figure 6).  
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Discussion 
Here we demonstrate that the administration of a large dose (1000 IU/kg s.c.) of EPO 1 h after 
LPS administration or CLP attenuates AKI. Most notably, we describe for the first time that the 
observed beneficial effects of EPO in WT mice subjected to either endotoxemia or sepsis were 
not observed in mice, which lacked the βcR. In 2004, Brines and colleagues proposed that the 
tissue protective effects of EPO and its derivatives might be mediated (at least in part), by the 
βcR 22. The βcR is a signal transduction subunit, which is shared by the α-chain subunits of 
the IL-5, IL-3 and GM-CSF receptors 37. The α-chains are able to bind their ligand with low 
affinity (1-100nM), but the hetero-receptors are not able to signal in the absence of the βcR. 
On the other hand, the βcR does not measurably bind a ligand by itself, but it amplifies a signal 
once a ligand has bound (in the picomolar range) 38, 39. The βcR is not required for 
erythropoiesis, as βcR KO mice have normal erythrocyte maturation 22. The EPOR functionally 
associates with the βcR 40, 41 to generate an EPOR-βcR complex, the latter of which has been 
proposed to mediate the tissue-protective effects of EPO. In mice, the βcR was expressed 
(mRNA) in both cortex and medulla of the kidney. Our finding that the renoprotective effects 
of EPO in endotoxemia/sepsis are lost in βcR KO mice supports our hypothesis that the βcR 
is essential for the ‘tissue-protective’ effects of EPO in sepsis.  
There is now increasing evidence that the renal dysfunction (AKI) associated with sepsis in 
patients is secondary to functional rather than structural changes. Although some 
morphological abnormalities have been reported in kidneys from patients, which died from 
sepsis, these changes were relatively small and are unlikely to account for the profound renal 
dysfunction observed in these patients. For instance, despite the high prevalence of clinical 
renal dysfunction (65%) in 20 patients, which died from sepsis and multiple organ dysfunction, 
only one septic patient had evidence of kidney necrosis. No renal tubular or glomerular cell 
apoptosis was seen in any of these septic patients. Hence, in patients without preexisting renal 
disease, renal histology did not reflect the severity of renal injury indicated by the decrease in 
kidney function (Hotchkiss CCM, 1999). We show here that mice subjected to endotoxemia 
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for 18 h have a profound renal dysfunction in the absence of overt morphological alterations 
or even increases in biomarkers of apoptosis (cleaved caspase-3) or proximal tubular injury 
(or KIM-1) in the kidney. As EPO did not affect any of the above (minimal) signs of injury, it is 
unlikely that the reduction in renal dysfunction afforded by EPO in sepsis is secondary to 
prevention of renal injury. 
What, then, are the signaling events that are activated by EPO via the βcR? There is evidence 
that the beneficial effects of EPO are secondary to the activation of the survival kinase Akt 42-
45. Akt is a member of the phosphoinositide 3-kinase signal transduction enzyme family, which 
regulates cellular activation, inflammatory responses, chemotaxis, and apoptosis 46. When 
phosphorylated by its upstream regulator, phosphoinositide-dependent kinase, Akt modulates 
cell survival and growth 46. We document here that EPO causes the activation of Akt in WT 
mice subjected to endotoxemia, while the activation of this pathway by EPO was lost in βcR 
KO mice. The above findings support the view that both, the βcR and the activation of Akt, are 
essential for the reported beneficial effects of EPO. 
What, then, are the downstream targets of Akt? There is good evidence that activation of Akt 
results in Ser9 phosphorylation of GSK-3β 47-49. GSK-3β is a serine-threonine kinase that was 
originally recognized as a kinase that phosphorylates glycogen synthase. In contrast to most 
other kinases, GSK-3β is active in a resting cell state and is regulated by multiple signaling 
pathways including the Akt pathway, which inhibits this kinase by causing Ser9 
phosphorylation 47, 48. Specific inhibitors of the activation GSK-3β attenuate the AKI caused by 
co-administration of LPS and peptidoglycan 50 and improve survival in endotoxemia 51. Agents 
that activate the PI3K/Akt pathway 47 also inhibit GSK-3β. We have previously reported that 
insulin activates Akt, inhibits GSK-3β and reduces AKI caused by LPS and peptidoglycan 52. 
We report here that EPO enhances the phosphorylation of the Ser9 residue of GSK-3β 
resulting in the inhibition of this kinase, which attenuates the renal dysfunction caused by LPS 
and peptidoglycan 53-55. This effect of EPO was lost in βcR KO mice. 
Downstream of GSK-3β, several studies have now reported an association between GSK-3β 
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and NF-κB activity in vitro 56, 57 and in vivo 50, 52. Treatment of TNF-α stimulated hepatocytes 
with a specific GSK-3β inhibitor resulted in a decrease of the NF-κB–dependent gene 
transcription 58. NF-κB is a transcriptional factor that plays an important role in regulating the 
transcription of a number of genes (e.g. iNOS, cyclooxygenase-2, IL-1, TNF, IL-6), especially 
those involved in producing mediators involved in local and systemic inflammation, such as 
cytokines, chemokines, cell adhesion molecules, apoptotic factors, and other mediators 59. 
The protective effects of inhibitors of GSK-3β in endotoxemia/sepsis have been attributed to 
inhibition of NF-ĸB secondary to either phosphorylation of Ser536 on the p65 subunit of NF-ĸB 
50 or prevention of the association of cAMP response element-binding (CREB) with p65 51. In 
addition, GSK-3β may also inhibit the activation of NF-κB by phosphorylating and degrading 
IκBα, which is required to prevent NF-κB translocation 57. All of these effects may contribute 
to the reported beneficial effects of inhibitors of GSK-3β in sepsis. We report here that EPO 
prevents the nuclear translocation of p65 and, hence, the activation of NF-ĸB. This effect of 
EPO was lost in βcR KO mice. All of the above findings support the view that EPO enhances 
the activation of Akt resulting in inhibition of GSK-3β and inhibition of the activation of NF-κB 
in a βcR-dependent fashion 
In addition to inhibiting the activation of GSK-3β, activation of Akt results in the phosphorylation 
of eNOS on Ser1177, which, in turn, causes activation of eNOS resulting in an enhanced 
formation of NO in the microcirculation. There is evidence that EPO enhances the 
phosphorylation of Ser residues on eNOS resulting in its activation 36, 60, 61. In endothelial cells, 
EPO causes eNOS activation, while inhibition of EPOR or βcR by neutralizing antibodies or 
small interfering RNA abolished the EPO-induced NO formation 61. Most notably, inhibition of 
the βcR abolished the EPO-induced increase and the phosphorylation of eNOS, Akt, Src or 
Janus kinase 2 61. The findings support the view that βcR plays a key role in the activation of 
eNOS by EPO in endothelial cells. We report here that the increase in Ser1177 phosphorylation 
of eNOS by EPO in the kidney is lost in βcR KO mice. While our study was under way, de 
Souza and colleagues also showed that the attenuation of sepsis-induced AKI by EPO in the 
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rat is associated with an increased expression of eNOS and inhibition of the activation of NF-
ĸB, which the authors attributed to an anti-inflammatory and endothelial protective effect. 36. 
In line with this study Rodrigues et al. reported recently in the same animal model that 24 h 
pre-treatment with continuous erythropoietin receptor activator (CERA) protected against 
sepsis induced AKI at 24 h, which was in part, attributable to a suppression of the inflammatory 
response. Interestingly, their results revealed that renal EpoR expression, which was down 
regulated in their model of sepsis, was preserved by pretreatment with CERA 16. 
In conditions associated with sepsis, activation of eNOS is beneficial as the enhanced 
formation of NO causes local vasodilation, inhibits adhesion of platelets and neutrophils, and 
regulates angiogenesis 62, 63. Agents that release NO or enhance the formation of endogenous 
NO may attenuate excessive intrarenal vasoconstriction and reduce renal dysfunction 64, 65. 
Thus, activation of eNOS (possibly secondary to activation of Akt) may contribute to the 
beneficial effects of EPO reported here.  
All of the above findings support the view that the βcR is essential for the following effects of 
EPO in mice with endotoxemia: 1) reduction of AKI; 2) activation of Akt; 3) activation of eNOS; 
4) inhibition of GSK-3β; and 5) inhibition of the activation of NF-ĸB. 
In order to investigate whether the βcR is also essential for the effects of EPO in polymicrobial 
sepsis, we developed a model of CLP induced AKI. We found that the degree of renal 
dysfunction increased with the age of the animals. We were unable to document a significant 
degree of AKI at 24 h after CLP in young (two and five months old) mice, while eight months 
old mice exhibited a very large increase in creatinine within 24 h after CLP. Most notably, 
administration of EPO (at 1 h after CLP) attenuated the AKI caused by polymicrobial sepsis in 
aging mice. In order to investigate the role of the βcR in this effect of EPO, we bred aged-
matched βcR KO mice. Using these animals, we demonstrate that the beneficial effects of 
EPO were lost in eight months old βcR KO mice. 
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In conclusion, our findings show convincingly for the first time that the βcR is essential in the 
reduction of the acute renal dysfunction caused by EPO in sepsis as well as all of the signaling 
events traditionally associated with the well-documented beneficial effects of EPO. 
 
Methods 
Animals 
The animal protocols followed in this study were approved by the local Animal Use and Care 
Committee in accordance with the derivatives of both the Home Office guidance on the 
Operation of Animals (Scientific Procedures Act 1986) published by Her Majesty’s Stationary 
Office and the Guide for the Care and Use of Laboratory Animals of the National Research 
Council. This study was carried out on 73 male WT C57BL/6 mice (Harlan Laboratories, 
Wyton, UK) and 73 male βcR KO mice on a C57/BL-6J genetic background (bred and 
maintained at Queen Mary University of London Biological Services Unit) receiving a standard 
diet and water ad libitum. We employed young (2 months) mice for the model of endotoxemia 
and old (8 months) mice for the model of polymicrobial sepsis. 
Endotoxemia 
In the model of endotoxemia-induced AKI, mice received either LPS (9 mg/kg in 5 ml/kg 0.9 % 
saline i.p.) or vehicle (5 ml/kg 0.9 % saline i.p.). One hour after induction of endotoxemia, mice 
were treated either with EPO (1000 IU recombinant human EPO in 10 ml/kg 0.9 % saline) or 
vehicle (10 ml/kg 0.9 % saline s.c.). Sham mice were not subjected to LPS-injection, but were 
otherwise treated in the same way. At 18 h the experiment was terminated and organ and 
blood samples were collected for quantification of organ injury. WT mice and βcR KO mice 
were randomly allocated into eight different groups. WT mice: (i) Sham + saline (n = 3); (ii) 
Sham + EPO (n = 3); (iii) LPS + saline (n = 9); (iv) LPS + EPO (n = 10); βcR KO mice: (v) 
Sham + saline (n = 3); (vi) Sham + EPO (n = 3); (vii) LPS + saline (n = 9); (viii) LPS + EPO (n 
= 20). 
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Polymicrobial sepsis 
In this study we developed a 24 h model of septic AKI induced by CLP in aged mice. We 
followed the original CLP protocol introduced by Wichterman and co-workers 66 with slight 
modifications, such as the antibiotic therapy (Imipenem/Cilastin; 20 mg/kg) and analgesia 
(buprenorphine; 0.05 mg/kg), which were administered 6 h after surgery and every 12 h after 
that. The detailed surgical procedure is described in the online supplementary file. To evaluate 
the time course of the development of renal dysfunction in mice of different ages, serum 
creatinine was measured in two, five and eight months old WT mice 24 h after CLP surgery. 
Finally, we established a model of severe, polymicrobial sepsis in 8-months old male WT mice, 
which developed reliable renal dysfunction 24 h after CLP. This model was then used to verify 
the effects of EPO on renal function obtained in the model of endotoxemia. At the beginning 
of the experiment, mice underwent CLP surgery. Sham mice were not subjected to CLP, but 
were otherwise treated in the same way. One hour after CLP, mice were treated either with 
EPO (1000 IU recombinant human EPO in 10 ml/kg 0.9 % saline s.c.) or vehicle (10 ml/kg 0.9 
% saline s.c.). WT mice and βcR KO mice were randomized into six different groups. WT mice: 
(i) Sham + saline (n = 3); (ii); CLP + saline (n = 10); (iii); CLP + EPO (n = 12). βcR KO mice: 
(iv) Sham + saline (n = 3); (v) CLP + saline (n = 6); (vi) CLP + EPO (n = 20). 
Quantification of organ injury 
All mice were anesthetized with 1.5 ml/kg i.p. of a ketamine (100 mg/ml)/xylazine (20 mg/ml) 
solution in a 2:1 ratio before being sacrificed. Approximately 1 ml of blood was collected by 
cardiac puncture into non-heparinized syringes and immediately decanted into serum gel 
S/1.3 tube (Sarstedt, Germany), after which the heart was removed to terminate the 
experiment. The samples were centrifuged at 9900 g for 5 min to separate serum, which was 
sent to an independent laboratory (IDEXX Laboratories, Buckinghamshire, UK) for analyses 
of serum creatinine and urea as markers of renal dysfunction as described in detail in the 
online supplement file. Additionally, kidney samples were taken, snap frozen and stored at -
80 oC for western blot analysis or fixed in 10% neutral buffered formalin for histological 
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evaluation. The detailed description of the histological evaluation of kidney tissues are 
available in the online supplementary. 
Western Blot Analysis 
Quantitative Western blot analysis was carried out as described previously 67. We assessed 
the degree of phosphorylation of Akt on Ser473, GSK-3β on Ser9, eNOS on Ser1177 and the 
nuclear translocation of the p65 subunit of NF-ĸB. The detailed method is described in the 
online supplementary file.  
Detection CSf2rb (encoding the βcR) gene expression in medulla and cortex of the 
kidneys of WT sham mice. 
Briefly, the medulla and the cortex were carefully dissected from the kidney and snap frozen. 
Samples were homogenized and RNA was extracted using RNeasy Mini Kit (Quiagen, 
Germany), according to manufacturers instructions. Reverse transcription polymerase chain 
reaction (RT PCR) was used to qualitatively detect gene expression through creation of 
complementary DNA (cDNA) transcripts from RNA. The detailed description of the detection 
CSf2rb (encoding the βcR) gene expression are available in the online supplementary.  
 
Materials 
Unless otherwise stated, all compounds in this study were purchased from Sigma-Aldrich 
Company Ltd (Poole, Dorset, UK). Antibodies for western blot analysis were purchased from 
Santa Cruz Biotechnologies (Middlesex, UK). All solutions were prepared using non-pyrogenic 
saline (0.9 % [w/v] NaCl; Baxter Healthcare Ltd., Thetford, Norfolk, UK). Recombinant human 
EPO (epoetin beta) was manufactured by Roche Diagnostics (Sussex, UK).  
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Statistical Analyses 
All values described in the text and figures are presented as mean ± standard error of the 
mean (SEM) of n observations, where n represents the number of animals studied. Statistical 
analysis was performed using GraphPad Prism 5.0d (GraphPad Software, San Diego, 
California, USA). Data without repeated measurements were assessed by one-way ANOVA 
followed by Dunnett’s post hoc test. A P-value of less than 0.05 was considered to be 
statistically significant. 
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Titles and legends 
Figure 1. Effect of EPO on renal dysfunction in endotoxemic WT and βcR KO mice. 
Serum urea (A, B) and serum creatinine (C, D) were measured 18 h subsequent to sham-
operation or LPS administration. Mice received either LPS (9 mg/kg in 5 ml/kg 0.9 % saline 
i.p.) or vehicle (5 ml/kg 0.9 % saline i.p.). One hour after induction of endotoxemia, mice were 
treated either with EPO (1000 IU EPO in 10 ml/kg 0.9 % saline s.c.) or vehicle (10 ml/kg 0.9 
% saline s.c.). WT mice (A, C): Sham + saline (n = 3); Sham + EPO (n = 3); LPS + saline (n 
= 9); LPS + EPO (n = 10). βcR KO mice (B, D): Sham + saline (n = 3); Sham + EPO (n = 3); 
LPS + saline (n = 9); LPS + EPO (n = 20). Data are expressed as means ± S.E.M. for n number 
of observations.  P < 0.05 vs. LPS + saline of WT or KO animals respectively.  
Figure 2. Effects of endotoxemia and/or EPO on renal morphology (light microscopy) 
and immunohistochemical staining for apoptosis [cleaved caspase-3 (CCR3)] kidney 
injury molecule-1 (KIM-1) 
Morphological (HE staining, A-F) and immunohistochemical [CCR 3 (G), KIM-1 (H)] 
evaluations were performed in kidneys obtained from mice 18 h after sham-operation or LPS 
administration. Mice received either LPS (9 mg/kg in 5 ml/kg 0.9 % saline i.p.) or vehicle (5 
ml/kg 0.9 % saline i.p.). One hour after induction of endotoxemia, mice were treated either 
with EPO (1000 IU EPO in 10 ml/kg 0.9 % saline s.c.) or vehicle (10 ml/kg 0.9 % saline s.c.). 
WT mice (A) Sham + saline (n = 4) (B) LPS + saline (n = 3); (C) LPS + EPO (n = 3). βcR KO 
mice (D): Sham + saline (n = 4); (E) LPS + saline (n = 4); (F) LPS + EPO (n =4). Evaluation 
by light microscopy (HE-staining) revealed that there was no overt morphological evidence of 
proximal tubular epithelial cell injury, interstitial edema, interstitial inflammation, vasculopathy 
or glomerular abnormality in any of the study groups and no treatment-related changes. (A-
F). Analysis of CCR3 (G) sections (apoptosis) revealed for no staining in sham-operated 
animals and a small increase in staining in all animals subjected to endotoxemia with no 
significant treatment-related changes. (P>0.05). The results of the Kim-1 IHC pathology 
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evaluation (H) showed slightly increased staining in the endotoxemic WT mice, which 
appeared reduced after treatment with EPO. There was no treatment-related change in the 
βcR KO mice. Overall, none of the observed changes in KIM-1 immunohistochemistry were 
statistically significant (P>0.05). 
 
Figure 3. Effect of EPO on the phosphorylation of Akt, GSK-3β and eNOS and on the 
nuclear translocation of the p65 NF-ĸB subunit in kidneys of WT and βcR KO mice with 
endotoxemia. Mice received either LPS (9 mg/kg in 5 ml/kg 0.9 % saline i.p.) or vehicle (5 
ml/kg 0.9 % saline i.p.). One hour after induction of endotoxemia, mice were treated with either 
EPO (1000 IU EPO in 10 ml/kg 0.9 % saline s.c.) or vehicle (10 ml/kg 0.9 % saline s.c.). Each 
band is from a single western blot experiment that is representative of three separate 
experiments. Data are expressed as means ± S.E.M. for n number of observations.  P < 
0.05 vs. LPS + saline of WT or KO animals respectively (white bars).  P < 0.05 vs. LPS + 
saline of WT or KO animals respectively (black bars). Panel A–C: Densitometric analysis of 
the bands (semi-quantitative Western blot analysis) is expressed for all groups studied as 
relative optical density (OD) of (A) phosphorylated Akt (pSer473) and the corresponding total 
Akt content (Σ Akt); (B) phosphorylated GSK-3β (pSer9) and the corresponding total GSK-3β 
content (Σ GSK-3β); (C) phosphorylated eNOS (pSer1117) and the corresponding total eNOS 
content (Σ eNOS). All values were corrected for the corresponding β-actin and normalized 
using the related sham-operated band. Panel D: Densitometric analysis of the bands is 
expressed for all groups studied as relative optical density (OD) for NF-ĸB p65 subunit levels 
in both, cytosolic and nuclear fractions normalized using the related sham operated band.  
Figure 4. The development of renal dysfunction in aging mice following CLP. Serum 
creatinine levels were measured 24 h subsequent to sham-operation or CLP-surgery in WT 
mice at different ages (two, five and eight months). Data are expressed as means ± S.E.M. 
for n number of observations.  P < 0.05 vs. sham. Sham (2 months, n = 3); CLP (2 months, 
n = 3); CLP (5 months, n = 5); CLP (8 months, n = 10). 
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Figure 5. Effect of EPO on renal dysfunction in septic WT and βcR KO mice. Serum 
creatinine levels were measured 24 h subsequent to sham-operation (no CLP) or CLP-surgery 
in WT (A) and βcR KO mice (B). One hour after CLP surgery mice were treated s.c. either with 
EPO (1000 IU recombinant human EPO in 10 ml/kg 0.9 % saline s.c.) or vehicle (10 ml/kg 0.9 
% saline s.c.). WT mice: Sham + saline (n = 3); Sham + EPO (n = 3); CLP + saline (n = 10); 
CLP + EPO (n = 12). βcR KO mice: Sham + saline (n = 3); CLP + saline (n = 6); CLP + EPO 
(n = 20). Data are expressed as means ± S.E.M. for n number of observations.  P < 0.05 vs. 
CLP + saline of WT or βcR KO animals respectively. 
Figure 6. Amplification of a CSf2rb gene fragment using cDNA from medulla or cortex 
of the kidneys of WT sham mice as template. 
Messenger RNA was extracted from medulla or cortex of WT sham mice and subjected to 
reverse transcription. PCR performed with cDNA yielded amplicons with a calculated 
molecular size of 326 bp, when separated in a 1 % agarose gel. GAPDH served as extraction 
control. Furthermore, the intensity of the 175 bp GAPDH band confirmed comparative loading 
of the gel lanes. 
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